Biogen Idec Inc.: Tecfidera Continues Its Blistering Pace

06-02-2014 Motley FoolComments (0)

Biogen IdecCNS DiseasesEisaiFranceGilenyaNeurologicalNovartisPharmaceuticalSanofiUSA

It's hard not to say that Tecfidera qualifies as one of the most impressive drug launches of 2013. Sales of Biogen's (NASDAQ: BIIB ) new multiple sclerosis treatment surged following the FDA's approval last spring. The company's new oral alternative to ...

Read more on Motley Fool

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top